Vantas Approval History
- FDA approved: Yes (First approved October 12th, 2004)
- Brand name: Vantas
- Generic name: histrelin
- Dosage form: Implant
- Company: Valera Pharmaceuticals
- Treatment for: Prostate Cancer
Vantas (histrelin) implant is an LHRH agonist administered once-yearly for the palliative treatment of advanced prostate cancer.
Development History and FDA Approval Process for Vantas
|Oct 12, 2004||Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.